首頁 > 市場調查報告書 > 製藥

感染疾病

市場調查報告書

商品編碼

2126592

HIV相關脂肪代謝障礙治療市場：依脂肪代謝障礙類型、治療類型、銷售管道和地區分類。

HIV-Associated Lipodystrophy Treatment Market, By Lipodystrophy Type, By Therapeutic Class, By Distribution Channel, By Geography

出版日期: 2026年08月05日 | 出版商:

Coherent Market Insights | 英文 258 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

據估計，2026年愛滋病相關脂肪代謝障礙治療市值為1.992億美元，預計2033年將達到2.63億美元。預計從2026年到2033年，該市場將以4.0%的複合年成長率成長。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	1.992億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	4.00%	2033年市場規模預測：	2.63億美元

市場成長的主要促進因素包括：接受長期抗逆轉濾病毒治療的人數不斷增加、人們對愛滋病相關脂肪重新分佈障礙的認知不斷提高、對諸如替沙莫瑞林等藥物療法的需求不斷成長，以及用於治療面部脂肪萎縮和異常脂肪堆積的美容和重組手術日益普及。此外，愛滋病患者生存率的提高、對患者生活品質的日益重視以及獲得專業愛滋病護理服務的途徑不斷擴大，也為市場發展提供了支持。

HIV相關性脂肪代謝障礙的特徵是HIV感染者體內脂肪分佈異常，表現為脂肪萎縮（皮下脂肪減少）或脂肪堆積（脂肪過度堆積在腹部、頸部、乳房和上背部等部位）。治療通常包括生長激素、生長激素釋放因子（GHRF）類似物、合成代謝類固醇、胰島素抗性調節劑、二甲雙胍、胰島素增敏劑酮類藥物、粒線體抗氧化劑和其他代謝藥物。對於出現臉部脂肪萎縮的患者，也可考慮重組手術或注射填充劑。

治療方法正逐漸從控制可見的脂肪重新分佈轉向更全面地管理腹型肥胖、胰島素抗性、血脂異常症、METABOLIC INC.症候群、心血管風險以及其他與愛滋病毒感染和抗逆轉錄病毒療法相關的長期併發症。這種轉變促使人們對定期代謝評估、身體組成監測、藥物治療、飲食管理以及涉及愛滋病專家、內分泌學家、營養師、皮膚科醫生和整形外科醫生等多學科協作的綜合護理的需求日益成長。

市場動態

由於長期抗逆轉錄病毒療法 (ART) 的使用日益普及，以及 ART 相關體重增加、中心性肥胖、胰島素阻抗和其他身體組成改變的發生率不斷上升，治療 HIV 相關脂肪代謝障礙的市場正在蓬勃發展。隨著 HIV 感染者生存期的延長，醫療專業人員越來越關注慢性代謝和心血管併發症，而不僅限於病毒抑制和感染疾病控制。

HIV感染者心臟代謝負擔加重，凸顯了早期診斷和早期療育的必要性。內臟脂肪堆積可能與葡萄糖耐受不良、低高密度高三酸甘油脂血症、高血壓、胰島素抗性和心血管併發症有關。因此，需要更積極地進行代謝篩檢、評估腹部脂肪、調整生活方式、藥物治療以及轉診至專科醫生。

對標靶治療的需求也是推動市場成長的因素之一。 Tesamorelin 仍然是治療 HIV 相關脂肪代謝障礙成人患者減少腹部脂肪的重要藥物。 2025 年 3 月，美國 FDA 批准了 EGRIFTA WR，進一步拓展了該患者群體的標靶治療選擇。然而，市場仍受到許多因素的限制，例如獲批的標靶治療藥物數量有限、治療費用高昂、醫保報銷障礙以及對少數特藥產品的依賴。

包括GLP-1受體促效劑在內的新型代謝療法可望拓寬未來的治療選擇。目前，研究人員正在研究這些療法能否降低HIV感染者的體重、腹部脂肪、內臟脂肪組織以及相關的代謝併發症。然而，這些產品要成為現有脂肪代謝障礙療法的直接競爭對手，還需要更多針對HIV的臨床證據和監管部門的批准。

專科藥房網路的擴展進一步改善了患者獲得治療的機會。由於愛滋病毒相關脂肪代謝障礙通常以門診治療為主，普通藥房和專科藥房在處方箋、核實保險、協助預先核准、更新和調整處方箋、接收患者以及宅配注射藥物等方面發揮著至關重要的作用。

本次調查的主要特點

本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
本研究根據以下參數分析了 HIV 相關脂肪代謝障礙治療市場中主要公司的概況：公司概況、產品系列、主要亮點、財務表現和策略。
本報告提供的見解將使行銷負責人和企業經營團隊能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
《HIV相關脂肪代謝障礙治療市場》報告的目標受群眾外包括該行業的各種相關人員，例如投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
相關人員可以透過利用分析 HIV 相關脂肪代謝障礙治療市場中使用的各種策略矩陣來簡化決策過程。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太國家
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第8章競爭情勢

熱圖分析
市佔率分析
公司簡介
- Theratechnologies Inc.
- GlaxoSmithKline plc
- Novelion Therapeutics Inc.
- AstraZeneca plc
- AbbVie Inc.
- Bristol-Myers Squibb
- Recent Highlightsa
分析師意見

第9章

參考
調查方法
關於本公司

簡介目錄

Product Code: CMI1269

HIV-Associated Lipodystrophy Treatment Market is estimated to be valued at USD 199.2 Mn in 2026 and is expected to reach USD 263.0 Mn by 2033, growing at a compound annual growth rate (CAGR) of 4.0% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 199.2 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	4.00%	2033 Value Projection:	USD 263.0 Mn

Market growth is primarily driven by the increasing number of people receiving long-term antiretroviral therapy, rising awareness of HIV-associated fat-redistribution disorders, growing demand for pharmacological treatments such as tesamorelin, and increasing adoption of cosmetic and reconstructive procedures for managing facial lipoatrophy and abnormal fat accumulation. Improvements in HIV survival rates, greater emphasis on patients' quality of life, and expanding access to specialized HIV care are also supporting market development.

HIV-associated lipodystrophy involves abnormal body-fat redistribution among people living with HIV and may present as lipoatrophy, characterized by the loss of subcutaneous fat, or lipoaccumulation, involving excess fat deposition in areas such as the abdomen, neck, breasts, and upper back. Treatment commonly includes growth hormones, growth hormone-releasing factor analogues, anabolic steroids, insulin-resistance modulators, metformin, thiazolidinediones, mitochondrial antioxidants, and other metabolic agents. Reconstructive procedures and injectable fillers may also be considered for patients experiencing facial lipoatrophy.

The treatment landscape is gradually shifting from the management of visible fat redistribution toward the broader management of abdominal adiposity, insulin resistance, dyslipidemia, metabolic syndrome, cardiovascular risk, and other long-term complications associated with HIV and antiretroviral therapy. This shift is increasing demand for routine metabolic assessment, body-composition monitoring, pharmacological intervention, dietary management, and multidisciplinary care involving HIV specialists, endocrinologists, nutrition professionals, dermatologists, and reconstructive surgeons.

Market Dynamics

The HIV-associated lipodystrophy treatment market is gaining momentum owing to the growing use of long-term antiretroviral therapy and the increasing prevalence of ART-related weight gain, central adiposity, insulin resistance, and other body-composition changes. As people living with HIV experience longer survival, healthcare providers are increasingly focusing on chronic metabolic and cardiovascular complications rather than limiting treatment to viral suppression and infectious-disease management.

The increasing cardiometabolic burden among people with HIV is strengthening the need for early diagnosis and intervention. Visceral-fat accumulation may be accompanied by glucose intolerance, high triglyceride levels, low HDL cholesterol, hypertension, insulin resistance, and cardiovascular complications. This is encouraging greater use of metabolic screening, abdominal-fat assessment, lifestyle modification, pharmacological treatment, and specialist referrals.

Demand for targeted therapies is also supporting market growth. Tesamorelin remains an important pharmacological treatment for reducing excess abdominal fat among adults with HIV-associated lipodystrophy. The U.S. FDA approval of EGRIFTA WR in March 2025 strengthened the availability of targeted treatment options for this patient population. However, the market remains constrained by the limited number of specifically approved therapies, high treatment costs, reimbursement barriers, and dependence on a small number of specialty products.

Emerging metabolic treatments, including GLP-1 receptor agonists, may broaden the future treatment landscape. These therapies are being investigated for their ability to reduce body weight, abdominal fat, visceral adipose tissue, and related metabolic complications among people living with HIV. Nevertheless, further HIV-specific clinical evidence and regulatory approvals will be necessary before these products become direct competitors to established lipodystrophy therapies.

The expansion of specialty-pharmacy networks is further improving access to treatment. As HIV-associated lipodystrophy is generally managed on an outpatient basis, retail and specialty pharmacies play an important role in prescription fulfilment, insurance verification, prior-authorization assistance, refill coordination, patient onboarding, and home delivery of injectable therapies.

Key Features of the Study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the HIV-Associated Lipodystrophy Treatment Market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Theratechnologies Inc., GlaxoSmithKline plc, Novelion Therapeutics Inc., AstraZeneca plc, AbbVie Inc., and Bristol-Myers Squibb.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The HIV-Associated Lipodystrophy Treatment Market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the HIV-Associated Lipodystrophy Treatment Market

Market Segmentation

By Lipodystrophy Type (Revenue, USD Mn, 2021-2033)
Lipoatrophy
Lipoaccumulation
By Therapeutic Class (Revenue, USD Mn, 2021-2033)
Anabolism modulators
Growth hormones
Anabolic steroids
Insulin resistance modulators
Metformins
Thiazolidinediones
Mitochondrial antioxidants (l-carnitine)
Miscellaneous metabolic agents
By Distribution Channel (Revenue, USD Mn, 2021-2033)
Hospital pharmacies
Retail pharmacies
Online pharmacies
By Region (Revenue, USD Mn, 2021-2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC
- Israel
- Rest of Middle East
Africa
- South Africa
- Central Africa
- North Africa
Key Players
Theratechnologies Inc.
GlaxoSmithKline plc
Novelion Therapeutics Inc.
AstraZeneca plc
AbbVie Inc.
Bristol-Myers Squibb

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Overview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Lipodystrophy Type
- Market Snapshot, By Therapeutic Class
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Market Trends
Key Developments
Product Approval
Collaboration/Merge/Acquisition
Regulatory Landscape
PEST Analysis
Porter's Five Forces Analysis
Epidemiology
Robust Pipeline Analysis

4. Global HIV-Associated Lipodystrophy Treatment Market, By Lipodystrophy Type, 2021 - 2033, (USD Million)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
Lipoatrophy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
Lipoaccumulation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)

5. Global HIV-Associated Lipodystrophy Treatment Market, By Therapeutic Class, 2021 - 2033, (USD Million)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
Anabolism modulators
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
Growth hormones
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
Anabolic steroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
Insulin resistance modulators
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
Metformins
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
Thiazolidinediones
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
Mitochondrial antioxidants (l-carnitine)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
Miscellaneous metabolic agents
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)

6. Global HIV-Associated Lipodystrophy Treatment Market, By Distribution Channel, 2021 - 2033, (USD Million)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
Hospital pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
Retail pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
Online pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)

7. Global HIV-Associated Lipodystrophy Treatment Market, By Region, 2021 - 2033, (USD Million)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Lipodystrophy Type, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Class, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Million)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Lipodystrophy Type, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Class, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Million)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Lipodystrophy Type, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Class, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Million)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Lipodystrophy Type, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Class, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Million)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Lipodystrophy Type, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Class, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Million)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Lipodystrophy Type, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Class, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Million)
  - North Africa
  - Central Africa
  - South Africa

8. Competitive Landscape

Heat Map Analysis
Market Share Analysis
Company Profile
- Theratechnologies Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- GlaxoSmithKline plc
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Novelion Therapeutics Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- AstraZeneca plc
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- AbbVie Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Bristol-Myers Squibb
  - Company Highlights
  - Product Portfolio
  - Financial Performance
- Recent Highlightsa
  - Market Strategies
Analyst Views